158 related articles for article (PubMed ID: 20509976)
1. Five-year follow-up of Japanese patients with Paget's disease of the bone after treatment with low-dose oral alendronate: a case series.
Iba K; Takada J; Wada T; Yamashita T
J Med Case Rep; 2010 May; 4():166. PubMed ID: 20509976
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial.
Reid IR; Nicholson GC; Weinstein RS; Hosking DJ; Cundy T; Kotowicz MA; Murphy WA; Yeap S; Dufresne S; Lombardi A; Musliner TA; Thompson DE; Yates AJ
Am J Med; 1996 Oct; 101(4):341-8. PubMed ID: 8873503
[TBL] [Abstract][Full Text] [Related]
3. Paget's disease of bone: experience from a centre in southern India.
Anjali ; Thomas N; Rajaratnam S; Shanthly N; Oommen R; Seshadri MS
J Assoc Physicians India; 2006 Jul; 54():525-9. PubMed ID: 17089899
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates for Paget's disease of bone in adults.
Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
[TBL] [Abstract][Full Text] [Related]
5. Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis.
Al Nofal AA; Altayar O; BenKhadra K; Qasim Agha OQ; Asi N; Nabhan M; Prokop LJ; Tebben P; Murad MH
Osteoporos Int; 2015 Jul; 26(7):1875-91. PubMed ID: 26037791
[TBL] [Abstract][Full Text] [Related]
6. Effects of two different bisphosphonates on Paget's disease of bone: ICTP assessed.
Filipponi P; Pedetti M; Beghe F; Giovagnini B; Miam M; Cristallini S
Bone; 1994; 15(3):261-7. PubMed ID: 8068446
[TBL] [Abstract][Full Text] [Related]
7. Management of Paget's disease of bone.
Langston AL; Ralston SH
Rheumatology (Oxford); 2004 Aug; 43(8):955-9. PubMed ID: 15187244
[TBL] [Abstract][Full Text] [Related]
8. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
[TBL] [Abstract][Full Text] [Related]
9. Asymptomatic Paget's disease of bone in a 62-year-old Nigerian man: three years post-alendronate therapy.
Aransiola CO; Ipadeola A
Endocrinol Diabetes Metab Case Rep; 2016; 2016():160005. PubMed ID: 26870373
[TBL] [Abstract][Full Text] [Related]
10. Risedronate: a new oral bisphosphonate.
Umland EM; Boyce EG
Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
[TBL] [Abstract][Full Text] [Related]
11. Radiological impact of oral bisphosphonate use on polyostotic Paget's disease of bone over a 2 year period.
Pinto CJ; Maldar SB; Hegde S; Choukimath SM
Radiol Case Rep; 2024 May; 19(5):1886-1892. PubMed ID: 38434784
[TBL] [Abstract][Full Text] [Related]
12. Alendronate in the treatment of Paget's disease of bone.
Khan SA; Vasikaran S; McCloskey EV; Benéton MN; Rogers S; Coulton L; Orgee J; Coombes G; Kanis JA
Bone; 1997 Mar; 20(3):263-71. PubMed ID: 9071478
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of drugs for Paget's disease of bone.
Reginster JY; Lecart MP
Bone; 1995 Nov; 17(5 Suppl):485S-488S. PubMed ID: 8573423
[TBL] [Abstract][Full Text] [Related]
14. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone.
Adami S; Zamberlan N; Mian M; Dorizzi R; Rossini M; Braga B; Gatti D; Bertoldo F; Locascio V
Bone Miner; 1994 May; 25(2):75-82. PubMed ID: 8086853
[TBL] [Abstract][Full Text] [Related]
15. [Paget's disease: case report].
Wegierska M; Ignaczak P; Zalewska J; Jeka S
Ann Acad Med Stetin; 2011; 57(3):64-9; discussion 69. PubMed ID: 23383549
[TBL] [Abstract][Full Text] [Related]
16. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and treatment of Paget's disease of bone : A clinical practice guideline.
Muschitz C; Feichtinger X; Haschka J; Kocijan R
Wien Med Wochenschr; 2017 Feb; 167(1-2):18-24. PubMed ID: 27600563
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.
Alvarez L; Guañabens N; Peris P; Vidal S; Ros I; Monegal A; Bedini JL; Deulofeu R; Pons F; Muñoz-Gomez J; Ballesta AM
Bone; 2001 Nov; 29(5):447-52. PubMed ID: 11704497
[TBL] [Abstract][Full Text] [Related]
19. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
[TBL] [Abstract][Full Text] [Related]
20. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.
Alvarez L; Peris P; Pons F; Guañabens N; Herranz R; Monegal A; Bedini JL; Deulofeu R; Martínez de Osaba MJ; Muñoz-Gómez J; Ballesta AM
Arthritis Rheum; 1997 Mar; 40(3):461-8. PubMed ID: 9082934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]